News brief­ing: Gilead re­veals more fil­go­tinib da­ta; Seagen and Astel­las re­port new co­hort for Pad­cev

Two months af­ter be­ing re­ject­ed by the FDA, Gilead still hasn’t de­cid­ed what to do with fil­go­tinib. And now they have an­oth­er batch of pos­i­tive da­ta to weigh in the bal­ance.

In­ves­ti­ga­tors say the drug came through in their Phase IIb/III study of the drug for mod­er­ate to se­vere ul­cer­a­tive col­i­tis, where Gilead had been look­ing to add on an ap­proval fol­low­ing an OK for rheuma­toid arthri­tis. Safe­ty is­sues, how­ev­er, put a halt to this dream, leav­ing the big biotech to pon­der over the fu­ture of a drug that it paid big to part­ner with Gala­pa­gos.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER